JNJ-79635322
Sponsors
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale, Universitaetsklinikum Heidelberg AöR, Janssen Cilag International, Janssen Research & Development, LLC, University of Heidelberg Medical Center
Conditions
Multiple MyelomaNewly Diagnosed Multiple Myeloma in patients eligible for stem cell transplantationPreviously Treated Amyloid Light-chain (AL) AmyloidosisRelapsed or Refractory
Multiple Myeloma (RRMM)Relapsed or Refractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma
Phase 1
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingNCT05652335
Start: 2022-11-22End: 2030-11-15Target: 180Updated: 2026-08-28
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
RecruitingNCT06768489
Start: 2024-12-04End: 2029-01-29Target: 240Updated: 2026-07-31
Phase 2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
RecruitingNCT05695508
Start: 2022-12-01End: 2029-09-15Target: 160Updated: 2025-12-24
A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS
RecruitingCTIS2023-505221-14-00
Start: 2023-12-04Target: 237Updated: 2026-01-26
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-,Talquetamab- and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
RecruitingCTIS2024-517382-17-00
Start: 2022-11-30Target: 130Updated: 2025-08-19
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07266441
Start: 2026-02-08End: 2028-12-12Target: 157Updated: 2026-08-28
A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Not yet recruitingCTIS2025-521976-80-00
Target: 28Updated: 2026-05-14
Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of
Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in
Participants With Relapsed/Refractory Multiple Myeloma
Not yet recruitingCTIS2025-524793-42-00
Target: 81Updated: 2026-08-26
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07258511
Start: 2026-02-04End: 2031-09-30Target: 400Updated: 2026-08-28
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingNCT07518186
Start: 2026-05-31End: 2032-12-08Target: 700Updated: 2026-08-28
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Not yet recruitingCTIS2025-522007-18-00
Target: 42Updated: 2026-05-19
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with
Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an
Anti-CD38 Antibody and Lenalidomide"
Not yet recruitingCTIS2025-523815-12-00
Target: 181Updated: 2026-07-03